CRISPR Therapeutics AG (NASDAQ:CRSP) Receives $71.75 Consensus Target Price from Analysts

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eighteen research firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have issued a buy rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $71.75.

Several analysts have recently weighed in on CRSP shares. Royal Bank of Canada dropped their price objective on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a "sector perform" rating for the company in a report on Wednesday, February 12th. Barclays dropped their price target on CRISPR Therapeutics from $56.00 to $42.00 and set an "equal weight" rating for the company in a report on Friday, May 9th. JMP Securities reissued a "market outperform" rating and issued a $86.00 price objective on shares of CRISPR Therapeutics in a research note on Wednesday, May 21st. Cantor Fitzgerald restated a "neutral" rating on shares of CRISPR Therapeutics in a research note on Wednesday, February 19th. Finally, Evercore ISI raised CRISPR Therapeutics from an "in-line" rating to an "outperform" rating and lifted their price target for the company from $60.00 to $99.00 in a report on Friday, February 14th.

CRISPR Therapeutics Stock Down 1.7%

NASDAQ:CRSP traded down $0.62 during trading hours on Tuesday, reaching $36.16. The company had a trading volume of 1,304,031 shares, compared to its average volume of 1,700,519. The stock has a 50-day moving average of $36.68 and a two-hundred day moving average of $41.58. CRISPR Therapeutics has a one year low of $30.04 and a one year high of $67.88. The firm has a market capitalization of $3.12 billion, a PE ratio of -8.26 and a beta of 1.88.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. The company's quarterly revenue was up 71.6% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.43) earnings per share. As a group, sell-side analysts expect that CRISPR Therapeutics will post -5.16 earnings per share for the current year.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 9,973 shares of the stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total value of $423,054.66. Following the transaction, the chief executive officer now owns 180,890 shares of the company's stock, valued at approximately $7,673,353.80. This represents a 5.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Julianne Bruno sold 1,198 shares of the business's stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total value of $50,819.16. Following the transaction, the chief operating officer now owns 8,263 shares of the company's stock, valued at $350,516.46. The trade was a 12.66% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 14,021 shares of company stock worth $594,771 over the last ninety days. Company insiders own 4.10% of the company's stock.

Hedge Funds Weigh In On CRISPR Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Bayforest Capital Ltd acquired a new stake in shares of CRISPR Therapeutics during the first quarter worth $423,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in CRISPR Therapeutics by 182.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,952,751 shares of the company's stock valued at $66,452,000 after purchasing an additional 1,262,560 shares during the last quarter. Woodline Partners LP grew its stake in CRISPR Therapeutics by 34.3% in the first quarter. Woodline Partners LP now owns 136,483 shares of the company's stock valued at $4,645,000 after purchasing an additional 34,883 shares in the last quarter. Millennium Management LLC increased its position in shares of CRISPR Therapeutics by 6,769.1% during the 1st quarter. Millennium Management LLC now owns 583,733 shares of the company's stock worth $19,864,000 after purchasing an additional 575,235 shares during the last quarter. Finally, AQR Capital Management LLC bought a new stake in shares of CRISPR Therapeutics during the 1st quarter worth approximately $861,000. Institutional investors and hedge funds own 69.20% of the company's stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.